Category: Latest News
-
Precision BioSciences shares jump after FDA grants Fast Track status to Duchenne therapy
Shares of Precision BioSciences (NASDAQ:DTIL) rose 13% on Monday after the U.S. Food and Drug Administration granted Fast Track designation to PBGENE-DMD, the company’s gene-editing therapy for Duchenne muscular dystrophy. The Fast Track designation is intended to accelerate the development and regulatory review of treatments for serious conditions. It also enables more frequent interactions with…
-
Korro shares jump 17% following $85M private placement financing
Korro Bio Inc. (NASDAQ:KRRO) shares climbed 17% on Monday after the company announced an oversubscribed $85 million private investment in public equity (PIPE) financing. The financing round was led by new investor Venrock Healthcare Capital Partners and included participation from both new and existing investors such as ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset…
-
Eltek shares gain nearly 4% after revenue tops expectations despite quarterly loss
Eltek Ltd. (NASDAQ:ELTK) reported fourth-quarter results on Monday that showed a loss of $0.05 per share while generating revenue of $13.24 million, representing a 23% increase from $10.8 million recorded in the same quarter a year earlier. The company said the year was affected by operational changes tied to the integration of new plating lines,…
-
Five key themes for markets in the week ahead
The conflict involving Iran continues to intensify at the start of the new week, pushing oil prices above $100 per barrel and fueling concerns about renewed global inflation pressures. At the same time, the Federal Reserve has entered its policy blackout period as a series of important inflation and labor market data releases approach. On…
-
Pfizer shares slip despite encouraging trial results for eczema treatment
Pfizer Inc (NYSE:PFE) shares declined 1.15% to $26.74 in premarket trading Monday, even after the pharmaceutical company reported positive mid-stage clinical trial results for its experimental antibody therapy targeting atopic dermatitis. The drugmaker said the antibody, tilrekimig, showed meaningful improvement in symptoms of the chronic inflammatory skin condition during the study. According to Pfizer, a…
-
Relmada Therapeutics shares jump 25% after promising bladder cancer trial results
Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) climbed 25% on Monday after the company released 12-month interim results from its Phase 2 study of NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The trial reported a 12-month complete response (CR) rate of 76%, while 95% of patients achieved a complete response at some point…
-
ZIM Integrated Shipping tops Q4 estimates as revenue comes in above forecasts
ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) reported fourth-quarter results on Monday that surpassed analyst expectations, posting adjusted earnings per share of $0.32 compared with the consensus estimate of a $0.99 loss. Revenue for the quarter totaled $1.48 billion, slightly above the analyst forecast of $1.45 billion. However, sales were down 32% from $2.17 billion recorded…
-
ACCO Brands shares drop more than 3% after weak outlook despite meeting earnings forecasts
ACCO Brands Corporation (NYSE:ACCO) released fourth-quarter results on Monday that met analyst earnings expectations but missed on revenue and included fiscal 2026 guidance that came in well below market forecasts. Shares of the company declined 3.58% in pre-market trading after the announcement, as investors focused on the weaker outlook despite the in-line quarterly earnings performance.…
-
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates
Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that came in ahead of analyst expectations, with the gene-editing company posting a smaller-than-expected loss and stronger revenue. The company reported a loss of $0.06 per share, beating the consensus estimate for a $0.23 loss. Revenue totaled $24.74 million, well above the analyst forecast of $8.02 million, although…
-
BETA Technologies shares slide as wider loss overshadows strong revenue growth
BETA Technologies, Inc. (NYSE:BETA) reported fourth-quarter revenue of $11.1 million on Monday, representing a 151% increase from $4.4 million in the same period a year earlier. However, the electric aerospace company posted a larger-than-expected loss, with adjusted earnings per share of -$2.02 for the quarter ended December 31, 2025. The company’s shares dropped 2.91% in…